246 related articles for article (PubMed ID: 23625457)
1. Recurrent gene fusions in prostate cancer: their clinical implications and uses.
Hessels D; Schalken JA
Curr Urol Rep; 2013 Jun; 14(3):214-22. PubMed ID: 23625457
[TBL] [Abstract][Full Text] [Related]
2. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
Shah RB; Chinnaiyan AM
Adv Anat Pathol; 2009 May; 16(3):145-53. PubMed ID: 19395877
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
4. Retention of Interstitial Genes between
Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
[No Abstract] [Full Text] [Related]
5. Truncated ERG proteins affect the aggressiveness of prostate cancer.
Wu F; Ding S; Lu J
Med Hypotheses; 2013 Apr; 80(4):490-3. PubMed ID: 23357671
[TBL] [Abstract][Full Text] [Related]
6. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.
Han B; Mehra R; Suleman K; Tomlins SA; Wang L; Singhal N; Linetzky KA; Palanisamy N; Zhou M; Chinnaiyan AM; Shah RB
Mod Pathol; 2009 Sep; 22(9):1176-85. PubMed ID: 19465903
[TBL] [Abstract][Full Text] [Related]
7. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA
Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210
[TBL] [Abstract][Full Text] [Related]
8. TMPRSS2-ERG gene fusion in prostate cancer.
Burdova A; Bouchal J; Tavandzis S; Kolar Z
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Dec; 158(4):502-10. PubMed ID: 25485532
[TBL] [Abstract][Full Text] [Related]
9. TMPRSS2-ERG fusions linked to prostate cancer racial health disparities: A focus on Africa.
Blackburn J; Vecchiarelli S; Heyer EE; Patrick SM; Lyons RJ; Jaratlerdsiri W; van Zyl S; Bornman MSR; Mercer TR; Hayes VM
Prostate; 2019 Jul; 79(10):1191-1196. PubMed ID: 31090091
[TBL] [Abstract][Full Text] [Related]
10. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases.
Alhamar M; Tudor Vladislav I; Smith SC; Gao Y; Cheng L; Favazza LA; Alani AM; Ittmann MM; Riddle ND; Whiteley LJ; Gupta NS; Carskadon S; Gomez-Gelvez JC; Chitale DA; Palanisamy N; Hes O; Trpkov K; Williamson SR
Histopathology; 2020 Dec; 77(6):890-899. PubMed ID: 32639612
[TBL] [Abstract][Full Text] [Related]
11. Protocols for Studies on TMPRSS2/ERG in Prostate Cancer.
Pakula H; Linn DE; Schmidt DR; Van Gorsel M; Vander Heiden MG; Li Z
Methods Mol Biol; 2018; 1786():131-151. PubMed ID: 29786791
[TBL] [Abstract][Full Text] [Related]
12. [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].
Guo XQ; Gui YT; Cai ZM
Yi Chuan; 2011 Feb; 33(2):117-22. PubMed ID: 21377967
[TBL] [Abstract][Full Text] [Related]
13. [TMPRSS2-ETS gene fusion in prostate cancer].
Perner S; Schmidt FH; Hofer MD; Kuefer R; Rubin M
Urologe A; 2007 Jul; 46(7):754-60. PubMed ID: 17458530
[TBL] [Abstract][Full Text] [Related]
14. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
[TBL] [Abstract][Full Text] [Related]
15. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
Helgeson BE; Tomlins SA; Shah N; Laxman B; Cao Q; Prensner JR; Cao X; Singla N; Montie JE; Varambally S; Mehra R; Chinnaiyan AM
Cancer Res; 2008 Jan; 68(1):73-80. PubMed ID: 18172298
[TBL] [Abstract][Full Text] [Related]
16. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
[TBL] [Abstract][Full Text] [Related]
17. Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer.
Rubin MA; Chinnaiyan AM
Lab Invest; 2006 Nov; 86(11):1099-102. PubMed ID: 16983328
[TBL] [Abstract][Full Text] [Related]
18. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.
Shah RB
Adv Anat Pathol; 2013 Mar; 20(2):117-24. PubMed ID: 23399797
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and clinical application of
Kong DP; Chen R; Zhang CL; Zhang W; Xiao GA; Wang FB; Ta N; Gao X; Sun YH
Asian J Androl; 2020; 22(2):200-207. PubMed ID: 31210145
[TBL] [Abstract][Full Text] [Related]
20. Androgen regulation of ETS gene fusion transcripts in prostate cancer.
Gasi D; Trapman J
Methods Mol Biol; 2011; 776():335-48. PubMed ID: 21796535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
